- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
April 12, 2021Robins Kaplan Executives Recognized by Twin Cities Business
-
April 1, 2021Robert Bennett Named a Midwest Trailblazer
-
March 31, 2021Robins Kaplan Attorneys Earn 2021 Readers' Choice Awards from JD Supra
-
April 28, 2021Creating the Audit Clause for Today’s Compliance Review
-
April 29, 2021International Intellectual Property: Challenges of Cross-Border Litigation
-
May 5, 12, and 19, 2021Second Annual AI Legal Summit
-
April 2, 2021Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
-
Spring 2021Fiduciary or Foe? Revisiting Meinhard v. Salmon
-
Spring 2021Shareholder Risks in Mergers and Acquisitions
-
April 14, 2021Financial Daily Dose 4.14.2021 | Top Story: Crypto Exchange Coinbase Makes Public Debut on Nasdaq
-
April 13, 2021Financial Daily Dose 4.13.2021 | Top Story: Ant Group Agrees to Sweeping Overhaul to Appease Chinese Regulators
-
April 12, 2021Financial Daily Dose 4.12.2021 | Top Story: Chinese Regulators Hit Alibaba With $2.8B Antitrust Fine
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Winter 2021
Winter 2021
The Winter 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
A few of the relevant court decisions highlighted in this issue:
- Eli Lilly & Co. v. Apotex, Inc.
Alimta® (pemetrexed disodium)
The Federal Circuit affirmed the district court’s finding that plaintiff’s amendment to replace “ALIMTA” with “pemetrexed disodium” was not a narrowing amendment. - Bracco Diagnostics Inc. v. Maia Pharms., Inc.
Kinevac® (sincalide)
The Federal Circuit affirmed the district court’s judgment based on the parties’ stipulation of infringement that resulted from the the district court’s claim construction. - Par Pharm., Inc. v. Hospira, Inc.
Adrenalin® (epinephrine injection)
The Federal Circuit affirms the trial court’s finding infringement.
Relevant ANDA Updates highlighted in this issue:
Related Professionals
Jeffrey Alan Hovden
Partner
Kelsey J. McElveen
Associate
Haroon N. Mian
Associate
Christopher A. Pinahs
Partner
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Alimta® (pemetrexed disodium)
Kinevac® (sincalide)
Adrenalin® (epinephrine injection)
Jublia® (efinaconazole)
Coreg® (carvedilol)
Impoyz® (clobetasol)
Quillivant XR® (methylphenidate (“MPH”))
Duexis® (ibuprofen / famotidine)
Subscribe to our quarterly GENERICally Speaking Update.
Subscribe Now
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.